Federica F. O'Brien
Known title: DirectorCIK: 0001140119
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Craig-Hallum initiates coverage on TELA Bio with $2 target. Craig-Hallum has started tracking TELA Bio, assigning a price target of $2. This new analyst note aligns with the current average analyst target of $2.08. The stock is currently trading above its 52-week low of $0.50, with recent technical indicators showing momentum near the upper end of its recent range.
Transaction History
| MGNX | ▲ Buy | Option Exercise | 3,750 | — | 5/18/2026 | View on chart |
| TELA | ▲ Buy | Grant | 7,950 | $0 | 5/28/2025 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 6,500 | — | 5/20/2025 | View on chart |
| TELA | ▲ Buy | Grant | 4,250 | $0 | 6/4/2024 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 4,500 | $0 | 5/20/2024 | View on chart |
| TELA | ▲ Buy | Grant | 3,135 | $0 | 6/1/2023 | View on chart |
| TELA | ▲ Buy | Grant | 3,135 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MGNX mentioned in medical stock sector review
MacroGenics was included in a recent Yahoo Finance article examining the performance of medical stocks this year. The stock is currently trading near its 52-week low, with technical indicators showing weakness near key support levels. This context highlights the broader sector trends affecting the company's valuation.
MGNX mentioned in medical stock sector review. MacroGenics was included in a recent Yahoo Finance article examining the performance of medical stocks this year. The stock is currently trading near its 52-week low, with technical indicators showing weakness near key support levels. This context highlights the broader sector trends affecting the company's valuation.